{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:52:08Z","timestamp":1791409928978,"version":"4.3.3"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010814","name":"Department of Education of Anhui Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010814","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009004","name":"Anhui University of Chinese Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009004","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bioorg.2026.110243","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T23:21:23Z","timestamp":1784071283000},"page":"110243","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Discovery of SH-17 as a pioneering STAT3\/HDAC bifunctional inhibitor that simultaneously impairs Tyr705 and Ser727 phosphorylation"],"prefix":"10.1016","volume":"181","author":[{"given":"Yulei","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuxiu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanchun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.110243_bb0005","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.chembiol.2010.05.011","article-title":"Targeting the undruggable proteome: the small molecules of my dreams","volume":"17","author":"Crews","year":"2010","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bioorg.2026.110243_bb0010","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41392-023-01589-z","article-title":"Recent advances in targeting the \u201cundruggable\u201d proteins: from drug discovery to clinical trials","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bioorg.2026.110243_bb0015","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/s41573-021-00199-0","article-title":"Advances in targeting \u2018undruggable\u2019 transcription factors with small molecules","volume":"20","author":"Henley","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2026.110243_bb0020","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/17460441.2021.1969359","article-title":"Strategies for targeting undruggable targets","volume":"17","author":"Zhang","year":"2022","journal-title":"Expert Opin. Drug Discovery"},{"key":"10.1016\/j.bioorg.2026.110243_bb0025","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1016\/j.scib.2024.03.056","article-title":"Targeting the undruggables-the power of protein degraders","volume":"69","author":"Zhang","year":"2024","journal-title":"Sci. Bull."},{"key":"10.1016\/j.bioorg.2026.110243_bb0030","doi-asserted-by":"crossref","first-page":"11280","DOI":"10.1021\/acs.jmedchem.9b01530","article-title":"Structure-based discovery of SD-36 as a potent, selective, and efficacious PROTAC degrader of STAT3 protein","volume":"62","author":"Zhou","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110243_bb0035","doi-asserted-by":"crossref","first-page":"10122","DOI":"10.1021\/acs.jmedchem.3c00079","article-title":"Exploitation of proximity-mediated effects in drug discovery: an update of recent research highlights in perturbing pathogenic proteins and correlated issues","volume":"66","author":"Zhao","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110243_bb0040","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1016\/j.cellsig.2013.05.007","article-title":"Regulation of STAT signaling by acetylation","volume":"25","author":"Zhuang","year":"2013","journal-title":"Cellular signaling"},{"key":"10.1016\/j.bioorg.2026.110243_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10090327","article-title":"The role of signal transducer and activator of transcription 3 (STAT3) and its targeted inhibition in hematological malignancies","volume":"10","author":"Arora","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bioorg.2026.110243_bb0050","doi-asserted-by":"crossref","first-page":"17471","DOI":"10.1074\/jbc.RA119.009801","article-title":"A thiazole-derived oridonin analogue exhibits antitumor activity by directly and allosterically inhibiting STAT3","volume":"294","author":"Shen","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2026.110243_bb0055","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13046-019-1206-z","article-title":"STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review","volume":"38","author":"Qin","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110243_bb0060","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nrc1275","article-title":"The STATs of cancer--new molecular targets come of age","volume":"4","author":"Yu","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2026.110243_bb0065","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.110243_bb0070","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/pcmr.12041","article-title":"Emerging molecular targets in melanoma invasion and metastasis","volume":"26","author":"Orgaz","year":"2013","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.bioorg.2026.110243_bb0075","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/med.20101","article-title":"STAT3: a critical transcription activator in angiogenesis","volume":"28","author":"Chen","year":"2008","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bioorg.2026.110243_bb0080","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.cmet.2017.11.001","article-title":"JAK\/STAT3-regulated fatty acid beta-oxidation is critical for breast cancer stem cell self-renewal and chemoresistance","volume":"27","author":"Wang","year":"2018","journal-title":"Cell Metab."},{"key":"10.1016\/j.bioorg.2026.110243_bb0085","doi-asserted-by":"crossref","first-page":"567","DOI":"10.4155\/fmc.11.22","article-title":"Signal transducer and activator of transcription 3 (STAT3): a promising target for anticancer therapy","volume":"3","author":"Masciocchi","year":"2011","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110243_bb0090","doi-asserted-by":"crossref","first-page":"20852","DOI":"10.1073\/pnas.0810958105","article-title":"Oncogenic kinase NPM\/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)","volume":"105","author":"Marzec","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bioorg.2026.110243_bb0095","doi-asserted-by":"crossref","first-page":"5952","DOI":"10.1038\/s41388-018-0379-9","article-title":"Histone deacetylase 6 regulates the immunosuppressive properties of cancer-associated fibroblasts in breast cancer through the STAT3-COX2-dependent pathway","volume":"37","author":"Li","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2026.110243_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111922","article-title":"Revisiting signal transducer and activator of transcription 3 (STAT3) as an anticancer target and its inhibitor discovery: where are we and where should we go?","volume":"187","author":"Huang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110243_bb0105","doi-asserted-by":"crossref","first-page":"8884","DOI":"10.1021\/acs.jmedchem.1c00629","article-title":"Recent update on development of small-molecule STAT3 inhibitors for cancer therapy: from phosphorylation inhibition to protein degradation","volume":"64","author":"Dong","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110243_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118329","article-title":"Discovery of a novel napabucasin derivative B16 as a potent STAT3 inhibitor for the treatment of triple-negative breast cancer","volume":"302","author":"Deng","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110243_bb0115","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.molonc.2015.02.012","article-title":"Hitting the right spot: mechanism of action of OPB-31121, a novel and potent inhibitor of the signal transducer and activator of transcription 3 (STAT3)","volume":"9","author":"Brambilla","year":"2015","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.bioorg.2026.110243_bb0120","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.3892\/ijo.2012.1568","article-title":"STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers","volume":"41","author":"Wang","year":"2012","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bioorg.2026.110243_bb0125","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nrm909","article-title":"STATs: transcriptional control and biological impact","volume":"3","author":"Levy","year":"2002","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bioorg.2026.110243_bb0130","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.pharmthera.2018.06.006","article-title":"Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we?","volume":"191","author":"Beebe","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bioorg.2026.110243_bb0135","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1126\/science.1169660","article-title":"Cell biology. Moonlighting in mitochondria","volume":"323","author":"Myers","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2026.110243_bb0140","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1126\/science.1164551","article-title":"Function of mitochondrial STAT3 in cellular respiration","volume":"323","author":"Wegrzyn","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2026.110243_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2018.101073","article-title":"Targeting STAT3 and oxidative phosphorylation in oncogene-addicted tumors","volume":"25","author":"Lee","year":"2019","journal-title":"Redox Biol."},{"key":"10.1016\/j.bioorg.2026.110243_bb0150","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1242\/jcs.193615","article-title":"Retraction: GRIM-19-mediated translocation of STAT3 to mitochondria is necessary for TNF-induced necroptosis","volume":"129","author":"Shulga","year":"2016","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.bioorg.2026.110243_bb0155","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.cyto.2016.05.019","article-title":"Mitochondrial STAT3: powering up a potent factor","volume":"87","author":"Garama","year":"2016","journal-title":"Cytokine"},{"key":"10.1016\/j.bioorg.2026.110243_bb0160","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41568-018-0090-8","article-title":"Therapeutically exploiting STAT3 activity in cancer-using tissue repair as a road map","volume":"19","author":"Huynh","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2026.110243_bb0165","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1126\/science.1171721","article-title":"Mitochondrial STAT3 supports Ras-dependent oncogenic transformation","volume":"324","author":"Gough","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2026.110243_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105992","article-title":"SAR study culminates in a series of HDAC6 selective inhibitors featuring Schisandrin C-analogous cap as potential immunomodulatory agents for cancer therapy","volume":"127","author":"Tao","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110243_bb0175","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1182\/blood.V116.21.115.115","article-title":"HDAC class I inhibition acetylates a non-histone protein STAT3 by modulating p300-STAT3-HDAC1 interaction in activated B-cell like (ABC) diffuse large B cell lymphoma","volume":"116","author":"Gupta","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.110243_bb0180","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1038\/leu.2011.340","article-title":"Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy","volume":"26","author":"Gupta","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2026.110243_bb0185","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-026-02950-1","article-title":"HDAC8 inhibition targets STAT3-MYC axis and synergizes with Venetoclax in KMT2A-rearranged acute myeloid leukemia","author":"Zhang","year":"2026","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2026.110243_bb0190","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3892\/mmr.2021.11947","article-title":"Chidamide induces apoptosis in DLBCL cells by suppressing the HDACs\/STAT3\/Bcl-2 pathway","volume":"23","author":"Zhang","year":"2021","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.bioorg.2026.110243_bb0195","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ejmech.2017.11.049","article-title":"Exploiting polypharmacology for improving therapeutic outcome of kinase inhibitors (KIs): an update of recent medicinal chemistry efforts","volume":"143","author":"Ma","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110243_bb0200","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1021\/acs.jmedchem.0c02111","article-title":"Discovery of novel pyrrolo[2,3-d]pyrimidine-based derivatives as potent JAK\/HDAC dual inhibitors for the treatment of refractory solid tumors","volume":"65","author":"Liang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110243_bb0205","doi-asserted-by":"crossref","first-page":"7468","DOI":"10.1021\/acs.jmedchem.1c00136","article-title":"Discovery of STAT3 and histone deacetylase (HDAC) dual-pathway inhibitors for the treatment of solid cancer","volume":"64","author":"Ren","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110243_bb0210","doi-asserted-by":"crossref","first-page":"14150","DOI":"10.1021\/acs.jmedchem.3c01242","article-title":"Discovery of novel fedratinib-based HDAC\/JAK\/BRD4 triple inhibitors with remarkable antitumor activity against triple negative breast cancer","volume":"66","author":"Zhao","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110243_bb0215","unstructured":"WO 2008\/044667 Al."},{"key":"10.1016\/j.bioorg.2026.110243_bb0220","unstructured":"CN 101522657 B."},{"key":"10.1016\/j.bioorg.2026.110243_bb0225","doi-asserted-by":"crossref","first-page":"12460","DOI":"10.1021\/acs.jmedchem.0c00830","article-title":"Thirty years of HDAC inhibitors: 2020 insight and hindsight","volume":"63","author":"Ho","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110243_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.128286","article-title":"Discovery of novel pyrazolopyrimidine derivatives as potent mTOR\/HDAC bi-functional inhibitors via pharmacophore-merging strategy","volume":"49","author":"Zhang","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110243_bb0235","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ejmech.2019.04.024","article-title":"Discovery of fluorescent coumarin-benzo[b]thiophene 1, 1-dioxide conjugates as mitochondria-targeting antitumor STAT3 inhibitors","volume":"174","author":"Cai","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110243_bb0240","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1021\/acscentsci.3c01440","article-title":"Discovery of the highly selective and potent STAT3 inhibitor for pancreatic cancer treatment","volume":"10","author":"Chen","year":"2024","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.bioorg.2026.110243_bb0245","doi-asserted-by":"crossref","first-page":"19184","DOI":"10.1021\/acs.jmedchem.5c01307","article-title":"Benzofuranyl-pyrazole as a novel scaffold for in vitro and in vivo potent anticancer therapeutics that directly disrupt the \u2018undruggable\u2019 MYC oncogene and potentiate immune checkpoint blockage","volume":"68","author":"Yang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110243_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.106146","article-title":"Discovery of selective HDAC6 inhibitors capped by flavonoid or flavonoid-analogous moieties as anti-cancer therapeutics simultaneously harboring anti-proliferative and immunomodulatory activities","volume":"129","author":"He","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110243_bb0255","doi-asserted-by":"crossref","first-page":"11751","DOI":"10.1021\/acs.jmedchem.4c00272","article-title":"Directly suppressing MYC function with novel alkynyl-substituted phenylpyrazole derivatives that induce protein degradation and perturb MYC\/MAX interaction","volume":"67","author":"Zhao","year":"2024","journal-title":"J. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826007790?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826007790?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:18:27Z","timestamp":1791407907000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826007790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":51,"alternative-id":["S0045206826007790"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110243","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of SH-17 as a pioneering STAT3\/HDAC bifunctional inhibitor that simultaneously impairs Tyr705 and Ser727 phosphorylation","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110243","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110243"}}